Xenon Pharmaceuticals Inc.
XENE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $8 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $77 | $1 | $0 | $0 |
| Gross Profit | -$77 | -$1 | $8 | $0 |
| % Margin | – | – | 100% | – |
| R&D Expenses | $77 | $75 | $61 | $59 |
| G&A Expenses | $19 | $19 | $19 | $18 |
| SG&A Expenses | $19 | $19 | $19 | $18 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$77 | -$1 | $0 | $0 |
| Operating Expenses | $19 | $94 | $80 | $77 |
| Operating Income | -$96 | -$94 | -$73 | -$77 |
| % Margin | – | – | -969.8% | – |
| Other Income/Exp. Net | $6 | $9 | $8 | $8 |
| Pre-Tax Income | -$90 | -$85 | -$65 | -$70 |
| Tax Expense | $1 | -$1 | $0 | -$4 |
| Net Income | -$91 | -$85 | -$65 | -$66 |
| % Margin | – | – | -867.3% | – |
| EPS | -1.15 | -1.07 | -0.83 | -0.84 |
| % Growth | -7.5% | -28.9% | 1.2% | – |
| EPS Diluted | -1.15 | -1.07 | -0.83 | -0.84 |
| Weighted Avg Shares Out | 79 | 79 | 79 | 78 |
| Weighted Avg Shares Out Dil | 79 | 79 | 79 | 78 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $7 | $8 | $9 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$90 | -$94 | -$72 | -$77 |
| % Margin | – | – | -961.1% | – |